argenx

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Established: 2008-01-01

Employees: -

Market Cap: $31.2B

Website: https://www.argenx.com/

Clinical Trials

A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Biological: Efgartigimod IV

First Posted Date: 2023-07-03

Last Posted Date: 2024-06-26

Lead Sponsor: argenx

Target Recruit Count: 33

Registration Number: NCT05927415

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇩🇪
APEX GmbH, Munich, Germany

Open Label Extension of Efgartigimod in Adults with Post-COVID-19 POTS

Phase 2

Terminated

Conditions: Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome

Interventions: Drug: Efgartigimod

First Posted Date: 2023-06-26

Last Posted Date: 2024-12-04

Lead Sponsor: argenx

Target Recruit Count: 33

Registration Number: NCT05918978

Locations: 🇺🇸
North Shore University HealthSystem, Glenview, Illinois, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 6 locations

ARGX-117 in Deceased Donor Kidney Transplant Recipients At Risk for Delayed Graft Function

Phase 2

Recruiting

Conditions: Delayed Graft Function

Interventions: Biological: ARGX-117
Other: Placebo

First Posted Date: 2023-06-18

Last Posted Date: 2024-11-27

Lead Sponsor: argenx

Target Recruit Count: 102

Registration Number: NCT05907096

Locations: 🇺🇸
Tampa General Hospital, Tampa, Florida, United States
🇺🇸
University of Illinois (UI) Health - Outpatient Care Center, Chicago, Illinois, United States
🇺🇸
The Ohio State University, Columbus, Ohio, United States

and more 37 locations

A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults

Phase 1

Completed

Conditions: Bioequivalence

Interventions: Biological: efgartigimod PH20 SC as a prefilled syringe presentation
Biological: efgartigimod PH20 SC as a vial + syringe presentation

First Posted Date: 2023-04-18

Last Posted Date: 2023-10-31

Lead Sponsor: argenx

Target Recruit Count: 120

Registration Number: NCT05817435

Locations: 🇺🇸
Investigator site 0010209, Tempe, Arizona, United States
🇺🇸
Investigator site 0010208, Lincoln, Nebraska, United States

A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)

Phase 2

Completed

Conditions: Primary Sjögren's Syndrome

Interventions: Biological: Placebo
Biological: Efgartigimod

First Posted Date: 2023-04-18

Last Posted Date: 2024-05-28

Lead Sponsor: argenx

Target Recruit Count: 34

Registration Number: NCT05817669

Locations: 🇵🇱
ETG Lublin, Lublin, Poland
🇵🇱
Clinical Research Center Spółka z ograniczoną odpowiedzialnością Medic-R Sp.k., Poznan, Poland
🇵🇱
MICS Centrum Medyczne Warszawa, Warszawa, Poland

and more 14 locations

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)

Phase 2

Terminated

Conditions: Membranous Nephropathy

Interventions: Other: placebo
Biological: efgartigimod IV

First Posted Date: 2023-04-13

Last Posted Date: 2024-11-22

Lead Sponsor: argenx

Target Recruit Count: 8

Registration Number: NCT05810961

Locations: 🇨🇳
Fujian Medical University Union Hospital, Fujian, China
🇨🇳
Fuyang People's Hospital, Fuyang, China
🇨🇳
Peking University People's Hospital, Beijing, China

and more 28 locations

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Lupus Nephritis (ZL-1103-013)

Phase 2

Recruiting

Conditions: Lupus Nephritis

Interventions: Biological: efgartigimod IV
Other: Placebo

First Posted Date: 2023-04-13

Last Posted Date: 2024-12-17

Lead Sponsor: argenx

Target Recruit Count: 60

Registration Number: NCT05810948

Locations: 🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳
Hunan Provincial People's Hospital, Changsha, China

and more 28 locations

A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants with Bullous Pemphigoid

Phase 3

Active, not recruiting

Conditions: Bullous Pemphigoid

Interventions: Biological: efgartigimod PH20 SC
Drug: Prednisone

First Posted Date: 2023-01-12

Last Posted Date: 2024-10-11

Lead Sponsor: argenx

Target Recruit Count: 160

Registration Number: NCT05681481

Locations: 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
🇨🇳
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China
🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States

and more 37 locations

A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

First Posted Date: 2023-01-04

Last Posted Date: 2024-08-23

Lead Sponsor: argenx

Target Recruit Count: 112

Registration Number: NCT05670704

Efficacy and Safety Study of Efgartigimod in Adults with Post-COVID-19 POTS

Phase 2

Completed

Conditions: Postural Orthostatic Tachycardia Syndrome

Interventions: Drug: Placebo
Drug: Efgartigimod

First Posted Date: 2022-12-01

Last Posted Date: 2024-10-03

Lead Sponsor: argenx

Target Recruit Count: 53

Registration Number: NCT05633407

Locations: 🇺🇸
University of California, San Diego Sulpizio Cardiovascular Center, La Jolla, California, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Stanford Movement Disorder Center, Palo Alto, California, United States

and more 8 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy